Here are some top formulation R&D interview questions for experienced professionals in oral solid dosage forms:
Q1: How do you approach formulation development for a new API with poor solubility?
A1: “I’d employ strategies like particle size reduction, solid dispersion, or complexation to enhance solubility. I’d also consider prodrug approaches or salt formation, depending on the API’s properties.”
Q2: What factors do you consider when selecting excipients for a formulation?
A2: “I’d consider factors like compatibility with the API, functionality (e.g., binder, disintegrant), stability, and regulatory compliance. I’d also evaluate excipient sources and suppliers to ensure quality and consistency.”
Q3: How do you optimize a formulation for manufacturability and scalability?
A3: “I’d focus on optimizing powder flow, compression properties, and tablet hardness. I’d also consider factors like blend uniformity, segregation potential, and equipment compatibility to ensure smooth manufacturing and scalability.”
Q4: Can you describe your experience with Quality by Design (QbD) principles in formulation development?
A4: “I’ve applied QbD principles to identify critical quality attributes (CQAs) and critical process parameters (CPPs). I’ve used design of experiments (DoE) and risk assessment to optimize formulations and ensure robustness.”
Q5: How do you troubleshoot issues with tablet or capsule formulations, such as poor dissolution or content uniformity?
A5: “I’d investigate root causes, such as API properties, excipient interactions, or manufacturing process issues. I’d use analytical techniques like HPLC, XRPD, or SEM to identify the issue and implement corrective actions.”
Q6: Can you discuss your experience with regulatory submissions and lifecycle management for oral solid dosage forms?
A6: “I’ve prepared and submitted regulatory dossiers, including formulation and manufacturing details. I’ve also managed post-approval changes, such as formulation or process modifications, and ensured compliance with regulatory requirements.”
Q7: How do you stay current with advancements in formulation technology and regulatory guidelines?
A7: “I attend industry conferences, participate in professional organizations, and follow regulatory updates. I also network with peers and stay informed about emerging trends and technologies in oral solid dosage formulation.”
Q8: Can you describe a challenging formulation project you’ve worked on and how you overcame obstacles?
A8: “I’d describe a project where I encountered issues like poor API solubility or stability. I’d explain how I applied scientific principles, collaborated with cross-functional teams, and implemented creative solutions to overcome the challenges.”
These questions assess the candidate’s expertise in formulation development, optimization, and regulatory compliance for oral solid dosage forms.
ABAC
